OMNIA Efficacy on Body Fat Mass Reduction
Palavras-chave
Resumo
Descrição
Overweight and obesity represent a serious public health issue. These conditions are characterized by an abnormal or excessive accumulation of body fat mass and they are related to an increase risk of developing chronic diseases such as cardiovascular, diabetes, arthrosis and certain kind of cancer (breast; colon). It's thus necessary to find new products able to counteract both overweight and obesity.
Omnia is a food supplement based on a Phaseolus vulgaris extract. It has pancreatic amylase inhibition properties.
In the following clinical trial, OMNIA will be administrated to a group of overweight subjects in order to evaluate its efficacy on reducing the body fat mass. Its action will be compared to a placebo administered to a second group of overweight volunteers with the same modalities as OMNIA.
datas
| Última verificação: | 09/30/2017 |
| Enviado pela primeira vez: | 07/27/2015 |
| Inscrição estimada enviada: | 08/02/2015 |
| Postado pela primeira vez: | 08/04/2015 |
| Última atualização enviada: | 10/30/2017 |
| Última atualização postada: | 10/31/2017 |
| Data real de início do estudo: | 07/31/2015 |
| Data Estimada de Conclusão Primária: | 05/31/2016 |
| Data Estimada de Conclusão do Estudo: | 02/28/2017 |
Condição ou doença
Intervenção / tratamento
Dietary Supplement: Omnia group
Dietary Supplement: Placebo group
Fase
Grupos de Armas
| Braço | Intervenção / tratamento |
|---|---|
| Experimental: Omnia group After 2 weeks of run-in period, subjects take 2 Omnia pills per meal (3 meals a day) for 12 weeks. | Dietary Supplement: Omnia group 12weeks of treatment |
| Placebo Comparator: Placebo group After 2 weeks of run-in period, subjects take 2 Placebo pills per meal (3 meals a day) for 12 weeks. | Dietary Supplement: Placebo group 12weeks of treatment |
Critério de eleição
| Idades qualificadas para estudar | 18 Years Para 18 Years |
| Sexos elegíveis para estudo | All |
| Aceita Voluntários Saudáveis | sim |
| Critério | Inclusion Criteria: - 25≤ BMI<30 kg/m2 - excess of fat mass - food habits : 3 meals a day and a glucides intake equivalent to at least 40% of daily energy (i.e.: glucides intake at each meal) - Able to give a written or verbal informed consent - Affiliated or beneficiary of social security Exclusion Criteria: - Weight loss/gain > 2kg within the preselection period (2 weeks) - Abnormal blood results at V0 - Physical activity (sport; lifestyle) modification planned or ongoing during the trial - Severe pathologies/disorders (bulimia; anorexia; diabetes; cancer…) emerging - Pregnancy during the study - Consent withdrawal - Allergy to Omnia - observance <60% - Investigator or promotor decision |
Resultado
Medidas de Resultado Primário
1. Reduction of body fat mass loss measured by DEXA (Dual-energy X-ray absorptiometry) [12 weeks]
Medidas de Resultado Secundário
1. change from baseline in Body Mass Index (BMI) [6, 12 weeks]
2. change from baseline on the ratio fat/lean body mass measured by DEXA [12 weeks]
3. change from baseline on weight [6, 12 weeks]
